847039-26-3

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]sulfonyl]-, 1,1-dimethylethyl ester
• CAS NO: 847039-26-3
• Molecular Formula: C16H21F3N2O5S
• Molecular Weight: 410.414
• Mol File: 847039-26-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]sulfonyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]sulfonyl]-, 1,1-dimethylethyl ester(847039-26-3)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]sulfonyl]-, 1,1-dimethylethyl ester(847039-26-3)

Safety Data

• Hazardous Substances Data: 847039-26-3(Hazardous Substances Data)

Upstream product

• 94108-56-2 4-(trifluoro-methoxy)benzene-1-sulfonyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1342253-49-9 8-methyl-7-{[4-({4-[(trifluoromethyl)oxy]phenyl}sulfonyl)-1-piperazinyl]carbonyl}quinoline 
• 756859-05-9 1‐(4‐(trifluoromethoxy)phenylsulfonyl)piperazine 

Relevant articles and documents

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.

PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS

The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.

DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS

Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionally substituted aryl, heteroaryl, C3-C8 cycloalkyl or heterocycloakyl group; R represents hydrogen or C1-C6 alkyl, or C3-C6 cycloalkyl; Alk represents a divalent C1-C5 alkylene or C2-C5 alkenylene radical; and R1 and R2 taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C3-C8 cycloalkyl or heterocycloalkyl ring, the said first and second rings being optionally substituted by at least one group of formula (II): formula (II) wherein m, p and n are independently 0 or 1; Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms; Alk1 and Alk2 independently represent optionally substituted divalent C1-C3 alkylene radicals; X represents -0-, -S-, -S(O)-, -S(O2)-, -C(=O)-, -NH-, -NR3-, -S(O2)NH-, -S(O2)NR3-, -NHS(O2)-, or -NR3S(O2)-, where R3 is C1-C3 alkyl.